Have your own idea? Try our Stock Screener
Norwegian (OSEAX) Biotech Industry Analysis
UpdatedJan 22, 2026
DataAggregated Company Financials
Companies9
- 7D-4.3%
- 3M4.8%
- 1Y27.4%
- YTD-1.9%
Over the last 7 days, the Biotech industry has dropped 5.3%, driven by a pullback from ArcticZymes Technologies of 10%. In contrast, Zelluna has gained 6.9%. Over the past 12 months, the industry was up 32%. Looking forward, earnings are forecast to grow by 25% annually.
Industry Valuation and Performance
Has the Norwegian Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Thu, 22 Jan 2026 | NOK 5.3b | NOK 606.1m | -NOK 366,843,812.34 | 77.9x | -14.3x | 8.7x |
| Sat, 20 Dec 2025 | NOK 5.0b | NOK 607.4m | -NOK 368,701,610.06 | 79.4x | -13.7x | 8.3x |
| Mon, 17 Nov 2025 | NOK 4.7b | NOK 612.9m | -NOK 429,056,045.12 | 81.4x | -10.9x | 7.6x |
| Wed, 15 Oct 2025 | NOK 4.8b | NOK 613.1m | -NOK 520,612,083.59 | 254x | -9.2x | 7.8x |
| Fri, 12 Sep 2025 | NOK 4.8b | NOK 612.8m | -NOK 491,526,545.36 | 245.8x | -9.7x | 7.8x |
| Sun, 10 Aug 2025 | NOK 4.8b | NOK 886.7m | -NOK 749,763,853.03 | 224.7x | -6.4x | 5.4x |
| Tue, 08 Jul 2025 | NOK 4.8b | NOK 885.3m | -NOK 745,378,255.83 | 199.7x | -6.4x | 5.4x |
| Thu, 05 Jun 2025 | NOK 4.6b | NOK 885.2m | -NOK 745,018,191.21 | 185.7x | -6.2x | 5.2x |
| Sat, 03 May 2025 | NOK 4.6b | NOK 519.6m | -NOK 1,017,926,030.51 | 112x | -4.5x | 8.9x |
| Mon, 31 Mar 2025 | NOK 4.6b | NOK 520.4m | -NOK 918,625,294.70 | 110.1x | -5x | 8.8x |
| Wed, 26 Feb 2025 | NOK 5.4b | NOK 471.8m | -NOK 1,117,223,421.98 | 125.5x | -4.8x | 11.4x |
| Fri, 24 Jan 2025 | NOK 5.1b | NOK 457.2m | -NOK 1,070,419,635.88 | 154.5x | -4.7x | 11.1x |
| Sun, 22 Dec 2024 | NOK 4.5b | NOK 457.5m | -NOK 1,072,731,079.48 | 148.5x | -4.2x | 9.8x |
| Tue, 19 Nov 2024 | NOK 3.7b | NOK 484.0m | -NOK 1,065,358,188.10 | 147.7x | -3.4x | 7.6x |
| Thu, 17 Oct 2024 | NOK 4.7b | NOK 471.9m | -NOK 1,069,434,351.30 | 55.9x | -4.4x | 10x |
| Sat, 14 Sep 2024 | NOK 5.3b | NOK 470.2m | -NOK 1,052,958,592.90 | 60.1x | -5x | 11.3x |
| Mon, 12 Aug 2024 | NOK 8.1b | NOK 515.6m | -NOK 1,048,313,840.85 | 69.8x | -7.7x | 15.7x |
| Wed, 10 Jul 2024 | NOK 8.5b | NOK 513.4m | -NOK 1,040,267,893.09 | 69.8x | -8.2x | 16.6x |
| Fri, 07 Jun 2024 | NOK 9.2b | NOK 640.8m | -NOK 938,122,873.79 | 37.5x | -9.8x | 14.3x |
| Sun, 05 May 2024 | NOK 8.7b | NOK 658.3m | -NOK 957,096,317.72 | 35.9x | -9.1x | 13.2x |
| Tue, 02 Apr 2024 | NOK 9.2b | NOK 658.7m | -NOK 944,695,486.66 | 40.9x | -9.8x | 14x |
| Thu, 29 Feb 2024 | NOK 14.4b | NOK 673.0m | -NOK 1,006,746,085.66 | 41x | -14.3x | 21.4x |
| Sat, 27 Jan 2024 | NOK 16.5b | NOK 656.0m | -NOK 1,357,631,062.00 | 59.2x | -12.2x | 25.2x |
| Mon, 25 Dec 2023 | NOK 15.8b | NOK 653.0m | -NOK 1,348,996,802.00 | 60.5x | -11.7x | 24.3x |
| Wed, 22 Nov 2023 | NOK 16.1b | NOK 659.7m | -NOK 1,368,362,220.00 | 56.3x | -11.7x | 24.4x |
| Fri, 20 Oct 2023 | NOK 15.7b | NOK 489.4m | -NOK 1,552,480,866.00 | 96.4x | -10.1x | 32.1x |
| Sun, 17 Sep 2023 | NOK 15.4b | NOK 625.5m | -NOK 1,462,609,751.00 | 56.8x | -10.6x | 24.7x |
| Tue, 15 Aug 2023 | NOK 16.6b | NOK 558.5m | -NOK 1,465,738,903.00 | 53.1x | -11.3x | 29.7x |
| Thu, 13 Jul 2023 | NOK 15.4b | NOK 554.5m | -NOK 1,449,758,095.00 | 57.8x | -10.6x | 27.7x |
| Sat, 10 Jun 2023 | NOK 16.2b | NOK 561.9m | -NOK 1,488,816,638.00 | 67.4x | -10.9x | 28.8x |
| Mon, 08 May 2023 | NOK 16.7b | NOK 522.6m | -NOK 1,456,115,518.00 | 55.3x | -11.5x | 32x |
| Wed, 05 Apr 2023 | NOK 15.8b | NOK 547.9m | -NOK 1,540,723,455.00 | 32.3x | -10.3x | 28.8x |
| Fri, 03 Mar 2023 | NOK 17.2b | NOK 536.2m | -NOK 1,678,220,635.00 | 30.4x | -10.2x | 32.1x |
| Sun, 29 Jan 2023 | NOK 18.0b | NOK 808.2m | -NOK 1,393,859,310.00 | 23.4x | -12.9x | 22.3x |
Price to Earnings Ratio
-12.9x
Current Industry PE
- Investors are pessimistic on the Norwegian Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 16.2x is higher than the industry's current PS ratio of 8.8x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have improved over the last three years.
- Meanwhile revenues for these companies have declined 9.2% per year.
- This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.
Industry Trends
Which industries have driven the changes within the Norwegian Healthcare industry?
| NO Market | 0.25% | |
| Healthcare | -1.78% | |
| Biotech | -4.35% | |
| Biotech | -4.35% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| ZLNA Zelluna | NOK 14.65 | 6.9% +NOK 25.0m | n/a | PS7261.4x | |
| PCIB PCI Biotech Holding | NOK 0.24 | 5.6% +NOK 485.2k | -81.0% | PS2x |